D. Boral Capital Reiterates Buy Rating for OS Therapies (NYSE:OSTX)

Posted by Alphonse Anthony on Feb 22nd, 2025

OS Therapies (NYSE:OSTX – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They presently have a $20.00 target price on the stock.

Separately, Maxim Group lifted their price target on shares of OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, January 16th.

View Our Latest Research Report on OS Therapies

OS Therapies Trading Down 10.1 %

Shares of NYSE:OSTX opened at $1.70 on Thursday. The company’s fifty day moving average price is $3.28 and its 200 day moving average price is $3.14. OS Therapies has a 12 month low of $1.58 and a 12 month high of $7.00.

Insider Buying and Selling

In other OS Therapies news, major shareholder Shalom Auerbach sold 100,000 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $2.84, for a total transaction of $284,000.00. Following the transaction, the insider now directly owns 2,431,211 shares of the company’s stock, valued at approximately $6,904,639.24. This trade represents a 3.95 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in OS Therapies stock. Virtu Financial LLC acquired a new position in shares of OS Therapies Inc (NYSE:OSTX – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

(Get Free Report)

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.